|
|
 |
FEATURED
ARTICLE
Research Wins the
Game Austin Supporter Debby
Cox Explains
READ
MORE | |
 |
 |
FUNDRAISING
UPDATES
"Why They Run" -
TNT documentary debuts
at Memphis Film Festival this month READ
MORE
Team In Training Is
Your Ticket in to the Sold-Out Nation's
Tri READ
MORE
Regatta Season is
Underway here are a few great
stories of outstanding
participants
READ
MORE
Gary Jobson Nominated President of US
Sailing READ MORE
Man & Woman of the
Year Sees More "Champions of Hope" Than Ever
Before READ
MORE
Make a Tribute
Donation to LLS in Honor of Your Mother
READ
MORE
Kendall Kollection
- Kicking off its Second
Year READ
MORE
| |
PATIENT
SERVICES
National Capital
Area Chapter donates technology to help students
in treatment stay in touch with
class/school READ
MORE
LLS bestows award
to outstanding social worker Nancy Boyle
READ
MORE
Upcoming Telephone
Education Programs READ
MORE
Featured Resources
READ
MORE
RESEARCH
This month, eNewsline
introduces the work of Sagar Lonial,
M.D.
READ MORE
Updates on TAP
clinical trials READ
MORE
ADVOCACY
Cancer Clinical Trials
Bills Introduced in Congress
READ MORE
ACT NOW! Urge Congress
to Co-Sponsor Access to Cancer Clinical Trails
Legislation
TAKE
ACTION

FROM THE
LLS BLOG READ MORE
| |
 |
|
|
 | | | | | |
|
|
|
Research Wins the Game Austin
Supporter Debby Cox Explains
Sometimes timing is
everything.
"If I had been talking to you
a year ago, I would be telling you that you have
three to five years to live and that we would be
doing a lot of different things to keep you
alive," Debby Cox's doctor told her after
diagnosing her with chronic myelogenous leukemia
(CML) on March 20,2002. "But today I am
happy to tell you that there is a great new
drug: Gleevec®,"
the doctor continued.
Gleevec is "the
magic pill" developed by The Leukemia &
Lymphoma Society (LLS) - funded researcher,
Brian Druker, M.D., of Oregon Health and Science
University Cancer Institute, thanks in large
part to hundreds of generous LLS donors whose
financial support helped keep his research
going. Cox, of Austin, Texas, also feels
strongly about the LLS research she and her
husband Rick support. They recently made a
commitment of $30,000 to support a portfolio of
researchers investigating CML at all levels from
basic science to therapy.
From her
initial diagnosis in 2002 to the decision to
make a major gift to research, there were many
years of involvement. Following her diagnosis,
Cox began to learn everything she could about
leukemia. Not surprisingly, everywhere she
turned, there was The Leukemia & Lymphoma
Society.
She saw a commercial on
TV advertising the Light The Night® Walk and decided to
raise money and attend the walk with her husband
and her daughter, Amanda. Light The Night Walk
is LLS's annual walk held in fall in communities
across the country to pay tribute to lives
touched by cancer. Participants carry
illuminated balloons - white for survivors, red
for supporters and gold for those who are
walking in memory of a loved one.
"This
lady who I had never seen before walked into our
office and said I have some money that I raised
for last night's walk and I need to give it to
you," says Jane Sierra, the former walk director
for the Central Texas Chapter of LLS. "Inside
the bag was $6,000 that Debby had raised
completely on her own." By the next year, she
was on the board and co-chairing Family Teams
for the Walk.
Although Cox loves Light
The Night Walk, for her it is all about the
research. "Each year it seems that
there are more and more of the white balloons of
survivors," she said. "Research is where we win
the game."
She also feels a
personal obligation.
"Someone else
contributed to create Gleevec and now my husband
and I want to be part of the next pill to help
the next person. I already know that Gleevec
will not work forever for me, so part of it is
selfish and part of it is knowing that something
good will come of it for others."
Another aspect about LLS that Cox
cherishes are the close friendships she has
formed with her fellow board members and the
staff.
"There is a true sense of
stewardship of both human relationships and
funds," she says. "I could only give to an
organization that I felt was completely genuine
and transparent." Elizabeth Muenzler, executive director of the Central Texas
Chapter of LLS, describes Cox this way: "She and
her husband honestly do not view themselves as
'philanthropists,' but rather small cogs in a
big wheel where everyone contributes to make the
world a better place. She is a humble,
fun-loving person who feels blessed to be able
to give when in fact we are the ones who are
lucky to have her."
Cox sums it up
more simply: "It's our version of 'paying it
forward.'"
Back to the
top
| | |
|
Why They
Run
Five Chicago metro area residents with
very different but equally compelling personal
stories are featured in a documentary film
"Why They
Run" that made its world premiere at
On Location:
Memphis, the Memphis International Film
Festival this month. The one thing
that all five had in common was the goal of
completing the Chicago Marathon and raising
money to support The Leukemia & Lymphoma
Society's (LLS) initiatives to fund research for
leukemia, lymphoma and myeloma. All signed on as
members of LLS's Team In
Training.
The film follows the five
as they take on the daunting challenge of
preparing for the marathon, despite physical and
emotional setbacks - they are older, out of
shape and overwhelmed by life's curveballs. The
cast: Lesley Spencer, 55, also the film's
producer, is a gifted composer; Marty Yundt, 53,
a SWAT police sergeant from Lake Zurich,
Illinois, and recovering from a divorce; Mimi
Noonan, 44, a mother whose son, Keegan, was
battling leukemia; Vanessa de Ingardia, 38, a
lymphoma survivor; Ron Williams, 70, a retired
marketing consultant who has completed 31
Chicago Marathons!
"I used to think
there was nothing I could do to make a
difference in the world," says Spencer. "But
since I joined TNT and started meeting the
people we're helping, I've learned that nothing
could be further from the truth. I've learned
that even a small thing can make a really big
difference in the life of a cancer
patient."
Directed by Olga Arango. The
film will be available for viewing online in May
at www.whytheyrun.com
Back to the
top
Regatta Season is
Underway
It's all hands on
deck for the 2009 Leukemia Cup Regatta season,
which is well under way, and across the country
sailors' commitment to the mission is as strong
as ever.
In New Orleans, Chuck Stuckey,
25, participates in the program in a slightly
unconventional way. On March 22, he kiteboarded
across Lake Ponchartrain to honor his father,
who died from acute myelogenous leukemia. He
raised $12,000 to support The Leukemia &
Lymphoma Society's blood cancer research and
patient services initiatives.
Grace
Palmer, 16, of Savannah, Georgia, sails to honor
her grandfathers, both of whom have multiple
myeloma. Over the four years she has been
participating in the Leukemia Cup Regatta she
has raised $29,000. The Savannah Yacht Club will
hold its Leukemia Cup Regatta the weekend of
September 19-21.
"I plan to participate
in LCR for as long as I am able to," says
Palmer. "My knowledge about sailing is something
I will always have and be able to use. It isn't
like other sports that you can only be good at
for a certain amount of time until you get too
old. Sailing in the Leukemia Cup Regatta has
been one of the best experiences of my life. I
think it is very important to raise money for a
cause. As a young person, fundraising is one of
the most effective ways that I can help find a
cure for these diseases." Monroe,
Washington police officer Ken Sahlstrom, 57,
sails in memory of his son, Jonathan, who lost
his battle to leukemia in 2006 at the age of 17.
He also sails to honor his nephew, Noah,
recently diagnosed with cancer. Sahlstrom is
joined by two fellow officers, Reid Weaver, who
lost his son Jackson to leukemia in 2006, and
Rick Dunn, whose son Callahan, is a leukemia
survivor. Both Callahan and Noah will join the
men in this year's sail. The Elliott Bay Marina
in Seattle will hold its Regatta on June 6. In
the four years that Sahlstrom and his fellow
police officers have participated in the Regatta
they have raised more than $11,000 to help fund
lifesaving research.
Lisa Thorndike, 68,
of southern New Jersey, was diagnosed in 1993
with solitary plasmacytoma which progressed to
multiple myeloma. She had two stem cell
transplants in 1997 and was in remission for 10
years. No longer in remission, Thorndike is
either going to participate in a clinical trial
or have a third stem cell transplant. Despite
her battles with the disease, Thorndike has been
undaunted in her dedication to the Leukemia Cup
Regatta. Her regatta fundraising has resulted in
$230,000 to help find a cure! Thorndike is
eligible for her 11th Fantasy Sail, taking place
in October in San Francisco. She will
participate in her 14th Leukemia Cup Regatta the
weekend of June 13 and 14 at the Keyport Yacht
Club in New Jersey.
For more information
about the 2009 Regatta series, please call
888.HELP.LLS or visit www.leukemiacup.org.
Back to the
top
Leukemia Cup Regatta Chairman Gary Jobson
in Line for US Sailing Post
US Sailing,
the national governing body of the sport,
announced last month at the group's spring
meeting in Denver that the Nominating and
Governance Committee intends to nominate Gary
Jobson of Annapolis, Md., as the organization's
next president. The position of president will
be elected by the board of directors at US
Sailing's Annual General Meeting in Houston Oct.
25, 2009. "US Sailing is a vital component of
our sport," said Jobson. "At this time in my
life, I look forward to serving the sport that
has been so good to me for so many years."
Jobson is the national chairman of The Leukemia
& Lymphoma Society's Leukemia Cup Regatta,
which has generated over $28 million to support
blood cancer research and patient
services.
Back to the top
Champions of
Hope
With over 500
candidates, LLS's Man & Woman of the Year
Campaign has more "champions of hope" than ever
in the history of the program.
During a
ten-week fundraising period beginning with a
kickoff celebration, the candidates are judged
solely on their success in raising money to help
LLS fund research to find cures and better
therapies, and provide information and support
to blood cancer patients and their families. The
local Man & Woman of the Year are the top
fundraisers in their community. The national
title is awarded to the top fundraisers in the
country, to be announced early this
summer.
Every dollar raised counts as one
"vote." The candidates compete in honor of LLS's
Boy & Girl of the Year, local children who
are blood cancer survivors and sources of
inspiration to others.
"The select
group of 2009 Man & Woman candidates are
carrying on the tradition of using their passion
and determination to raise funds that give
thousands of people battling blood cancers the
chance to live better, longer lives," said Blair
Fogle, the national manager of the program.
"Each year is even more thrilling. This is a
campaign that celebrates not only the individual
accomplishments, but the collective success of
all these amazing candidates."
To
learn more about this year's candidates, and the
campaign, visit www.manwomanoftheyear.org.
Back to the
top
This Mother's Day Celebrate a
Mother's Love Honor Your Mother
with a Tribute Gift to The Leukemia &
Lymphoma Society
For all the
acts of kindness, large and small, that mothers
perform on behalf of their children and other
loved ones every day, now is the perfect time to
do something special to pay tribute to
mothers.
Consider the heroic gesture
performed by Katy Moeller of Santa Monica,
Calif. There is nothing more terrifying for a
mother than to watch helplessly as her child
suffers. Moeller watched in agony as her
three-year-old daughter, Audrey, battled
leukemia several years ago. To honor her
daughter's battle, Moeller took on a physical
challenge of her own. She signed on with The
Leukemia & Lymphoma Society's Team In
Training and ran in the Carlsbad Marathon in
January 2008 while raising funds to support
live-saving blood cancer research, education and
patient services. Now five, Audrey has responded
well to treatment and living a fairly normal
life for a child her age.
"TNT enabled me
to do something positive for Audrey and all
others fighting blood cancers," Moeller
says.
Moeller's act is a powerful example
of a mother's love. Now you can do something
special to show appreciation for all the ways
that mothers such as Moeller do for others. You
can pay homage to your own mother by going to
www.lls.org/donate
and
making a donation, helping to ensure that every
child stricken with a blood cancer can live a
long and prosperous life. You can designate your
gift in honor of your mother and a special card
will be sent to her attention.
In order
to have the acknowledgement card sent by
Mother's Day your tribute donation must be made
by May 4!
Back to the top
Kendall Kollection - Kicking
off its Second Year
When
Jacqueline Savage McFee, a designer of popular
trendy school and office fashion products, got
the devastating news that her two-year-old
cousin, Kendall Sierens, was diagnosed with
leukemia, it brought things into perspective for
her. It also created a spark. The Kendall
Kollection - a collection of colorful high-end
school supplies inspired by the artist's young
cousin - was born in 2008 and has been raising
funds and awareness for The Leukemia &
Lymphoma Society (LLS). Now LLS has
announced it will be partnering with McFee again
this year in the hopes of raising even more
money to fight blood cancer.
The new
Kendall Kollection, including notebooks,
journals, laptop bags, pens, pencils, folders
will be featured in major retailers across the
country including Wal-Mart, Office Max, Staples,
and Kmart, beginning in May, 2009.
"Jackie's dynamic designs have been
drawing attention for several years now," says
Nancy L. Klein, LLS's chief marketing and
revenue officer. "LLS is so grateful to Jackie
and CP for recognizing the incredible impact
that using her talent to help raise awareness
and funds can have in the effort to find cures
and better therapies for patients with leukemia,
lymphoma and myeloma."
"Kendall is now
five-and-a-half and in remission, and to know I
could help to make a positive difference in her
life and her family by supporting LLS means the
world to me," says McFee. To learn more visit
www.jackiemcfee.com.
Back to the
top
| | |
|
National Capital Area Chapter Donates
Webcams Enabling Hospitalized Children to
Connect with Classrooms, Teachers and
Friends
This year, when six year-old Becky Wilson
of Arlington was about half way through first
grade and her leukemia was in remission, her
immune cell count dropped to a low level. It
became too risky for her to attend school or be
with friends at Jamestown Elementary School in
Arlington.
But thanks to a new program at
Georgetown made possible by The Leukemia &
Lymphoma Society's National Capital Area (NCA)
Chapter, Becky was able to stay in contact with
her teacher and classmates until she is able to
return to school via a new project at Georgetown
University Hospital that uses laptops and
webcams to link kids from the hospital to their
classrooms, teachers and friends. For example,
during one session, Becky was able to talk to
her classmates about recent assignments in
reading, and participate in discussions about
how the Great Wall of China was built and
weather disasters like tornadoes. Becky followed
along and took some notes. The children let her
know they made her a box of
Valentines.
The NCA Chapter conceived of the
idea and donated six laptops with built-in
webcams for the children at Georgetown and six
webcams for parents to take to their child's
school for classroom setup. This program is a
first for the local LLS chapter. The gift of the
equipment was made possible by the generous
donors who attended the 2008 Bobby Mitchell
TOYOTA Hall of Fame Golf Classic last summer.
The event is led by co-chairs Tammy Darvish of
DARCARS, Todd Heavner of Enterprise rent-a-car
and Bobby Mitchell.
"The National Capital Area
Chapter of The Leukemia & Lymphoma Society
is thrilled to be able to donate these webcams
to the children at Georgetown's Lombardi Cancer
Center," says Donna McKelvey, Executive Director
of the chapter. "We are so grateful to our
donors from The Bobby Mitchell TOYOTA Hall of
Fame Golf Classic for making this technology
available so that children who are taken out of
school due to cancer treatment can truly feel
like they are, once again, connected to their
classroom so that they can continue their
education alongside their
classmates."
Pediatric Hematology/Oncology
director Aziza Shad, M.D. said, "Having this
technology available is really a turning point
for children with cancer and other serious
illnesses. When some of our children are newly
diagnosed with leukemia they need to be out of
school for one to three years because they are
immune compromised from their chemotherapy. They
miss their teachers. They miss their friends.
These laptops with webcams provide a perfect way
for them to participate in a lesson and stay
connected with their school. We are very
grateful to The Leukemia & Lymphoma Society
for donating the equipment to make this
possible."
Mary Lane, L.I.C.S.W., clinical
social worker who helps children navigate school
and educational issues once they start cancer
treatment at Georgetown said it is
psychologically good for children to keep in
contact with their teachers and
friends.
"They can continue to feel
connected even if they're not there. Their
school and their friends are often a very
positive part of their life and it's important
to maintain those positive connections."
To learn more about pediatric
blood cancers, please visit:
Other
ways patients stay connected:
Back to the
top
 LLS Bestows First
Annual Award to Oncology Social Worker from
Oregon
The
Leukemia & Lymphoma Society is recognizing
the outstanding career of Nancy J. Boyle,
M.S.W., L.C.S.W., of Oregon Health &
Sciences University (OHSU), with the first LLS
Hematology-Oncology Social Worker of the Year
Award. The award will be presented on May 7 at
the annual Association of Oncology Social
Workers conference in Savannah, GA.
In
her 23-year career, the past 16 spent at OHSU,
Boyle has played an instrumental role in
supporting the psychosocial needs of both
pediatric and adult blood cancer patients
requiring bone marrow and stem cell
transplantation. She is sought out for her
expertise on the topic throughout the state and
across the country.
Among the
achievements for which she is being recognized
is the implementation of mandatory psychosocial
screening by a social worker for stem cell and
bone marrow transplant patients. Boyle developed
a multi disciplinary working committee and
within six months was overseeing a program that
was successfully transitioning patients through
the palliative care process.
Boyle has
partnered with LLS on numerous educational and
patient support programs, and regularly
coordinates with LLS on patient financial needs,
helping to create a seamless process to get
patients the assistance they need for
transportation and housing. She has played an
invaluable role in helping underinsured patients
find unrelated donors for life-saving stem cell
transplants.
"There were many candidates
for this award and each one of them was so
qualified and dedicated to the patients they
serve," said Hildy Dillon, senior vice president
of patient services for LLS. "Nancy's work has
been exemplary over her entire career and we
received many glowing letters of recommendation
submitted on her behalf. This award is testimony
to how important social workers are in
supporting patients when they are faced with a
devastating diagnosis. This is why LLS is
recognizing the critical work that social
workers like Nancy Boyle perform every day."
The colleagues who submitted letters on
her behalf also unanimously agreed that she not
only has established herself as an exceedingly
accomplished clinician, but as a leader among
social workers at OHSU, and across the state and
country. Nancy is valued by her colleagues and
patients for her wisdom, insights and
sensitivity, and many noted that she tirelessly
approaches her job with grace, humor and
compassion.
"I am overwhelmed by this
honor," said Boyle. "I know that I have a great
deal of wonderful colleagues who would also be
perfect candidates for this award. I am grateful
for the recognition and realize that it is not
lightly bestowed. I hope that I can continue to
reflect the values of AOSW and LLS, two
organizations that have been instrumental in my
development as an oncology social
worker."
Back to the
top
Upcoming Telephone Education
Programs (all
programs are free)
What: Myeloma:
Understanding Drug Therapy and Stem Cell
Transplantation When: Thursday,
May 14, noon - 1:30 p.m. ET Guest Speaker:
Seema Singhal, M.D., Division of
Hematology/Oncology, Northwestern
University
Register
online
What: CML: Understanding
Treatment, Monitoring Response When: Tuesday,
May 19, noon - 1 p.m. ET Guest Speaker:
Eric J. Feldman, M.D., New York-Presbyterian
Hospital/Weill Cornell Medical
College
Register online
What: Childhood Cancer
Survivorship: Challenges, Strategies,
Resources When: Tuesday
May 26, noon - 1:30 p.m. Guest Speaker:
Daniel Armstrong, Ph.D, University of Miami
Miller School of Medicine, Pediatrics, and Nancy
F. Cincotta, M.S.W., .L.C.S.W., A.C.S.W.,
B.C.D.,Psychosocial Director, Camp Sunshine,
Casco, Maine.
Register
online
Back to the
top
Featured
Resources
Funds are available
now!
Is it difficult or impossible
for you to afford medicine co-pays or your
health insurance premiums?
Funds are available for approved
patients with chronic myelogenous leukemia (CML)
who have a household income at or below 500%
above the US federal poverty guidelines. LLS is
changing lives by extending a helping hand when
patients need it the most.
Just ask Joe, a recent Co-Pay
Assistance Program recipient who has Medicare
Part D prescription coverage. "Without the help
I have received from LLS, I wouldn't have been
able to afford my lifesaving medicine," says
Joe. Julie, another patient with CML who has
benefited from the program, says, "My husband
has been laid off from his job. The money
has helped so much, especially now with the
economy the way it is. So my advice to others is
to check out the program and
apply!"
For more information, call
877-LLS-COPAY (877-557-2672).
You can also go online to www.LLS.org/copay, or send an e-mail
to copay@LLS.org.
Back to the
top
NEW National Education
Series Web Pages
Announcing the launch of our NEW National
Education Series pages for lymphoma, leukemia,
myeloma, MDS and survivorship on our website.
These new pages add a fresh new look and will be
easier to navigate for the user. We welcome you
to browse around these new easier friendly
pages.
Back to the
top
New Section of
Website
We
have added a new section to our Childhood Blood Cancers
page on juvenile myelomonocytic
leukemia, which includes basic information
about the disease and links to the JMML page and
the Chronic
myelomonocytic leukemia and Juvenile
myelomonocytic leukemia fact sheet.
The updated page is live now. We
invite you to take a look at your first
opportunity.
Back to the
top
Featured
Publications
Myeloma
Publications

- PS39 Myeloma
Details about symptoms, subtypes,
diagnosis, treatment, side effects, research,
resources.
- PS29 Mieloma SPANISH
- PS49 Myeloma: A Guide for Patients
and Caregivers
Basics
about symptoms, diagnosis, treatment, side
effects of treatment, research,
resources.
- PS42 Mieloma: Guia para pacientes
y las personas que los cuidan
CML
Publications
- PS31 Chronic Myelogenous
Leukemia
Details
about symptoms, subtypes, diagnosis, treatment,
side effects, research, resources.
- PS75 Leucemia mielogena cronica
SPANISH
- PS72 CML: A Guide for Patients and
Caregivers
Basics
about symptoms, diagnosis, treatment, side
effects of treatment, research,
resources.
- PS73 CML: Guia para pacientes y
las personas que los cuidan SPANISH
- PS71 My CML
Tracker
Explains
disease monitoring; tracker page for noting
appointments, test results, side effects.
- PS30 Mi Registro de CML
SPANISH
Detailed
disease descriptions, symptoms, diagnosis,
treatments, research and
resources.
Treatment
Related Publications
- PS40 Blood and Marrow Stem Cell
Transplantation
Details about stem cell transplants,
donor matching, treatment of potential
complications.
- PS65 Trasplante de celulas madre
sanguineas y de la medula osea
SPANISH
- PS44 Blood
Transfusion
Information on blood cells, safety
issues, potential complications and blood
donation.
- PS12 Understanding Clinical Trials
for Blood Cancers
How
clinical trials are planned, organized and
monitored, study types, safety,
eligibility.
- PS43 Understanding Drug Therapy
and Managing Side Effects
Drugs, drug administration, how they
affect the body, side effects, questions to
ask.
- PS76 Farmacoterapia y manejo de
los efectos secondarios SPANISH
- PS41 Understanding Lab and Imaging
Tests
Information
about blood cell counts, diagnostic and
prognostic tests, questions to ask.
- PS53 Informacion sobre las pruebas
de laboratorio y de imagenes
SPANISH
Back to the
top
| | |
 Sagar Lonial,
M.D. is associate professor, hematology/medical
oncology at Emory University in Atlanta. Dr.
Lonial, a recipient of a Translational Research
Program grant from LLS, is studying a
combination therapy for patients with myeloma
and other blood cancers.
What is the biomedical
problem/issue that you are trying to
resolve? The proteasome is a
piece of cellular machinery that removes
unnecessary proteins from cells. But in some
blood cancers, such as myeloma, the proteasome
may function abnormally. The targeted drug
Velcade (bortezomib) works for many myeloma
patients by inhibiting the proteasome. But
myeloma and other cancer cells can resist being
killed by Velcade. Our group is trying to better
understand how cancer cells become resistant and
if we can overcome that resistance, especially
by making Velcade more effective in combination
with other drugs.
What's novel or
innovative about your approach? Our
approach is novel because we are trying to
choose drug combinations based upon preclinical
evidence gathered in our laboratory studies,
rather than just randomly combining available
drugs. Our preliminary findings suggest that we
can really improve the efficacy of Velcade for
patients with myeloma by combining it with
Zarnestra (tipifarnib), an experimental drug
that has been shown to inhibit an enzyme that
can cause excessive growth of cancer cells.
Zarnestra really does not kill many myeloma
cells when used alone, but the anti-myeloma
effect of the combination is quite striking in
laboratory tests.
How will your work one
day help patients? We are currently
enrolling patients in an early phase clinical
trial based upon our laboratory data, and have
seen responses among patients with myeloma who
were resistant to Velcade as a single agent. We
are now testing higher dose levels and hope to
show that the combination is measurably more
effective in patients than Velcade alone, as is
true in laboratory tests.
Are you close to
clinical trials? The trial is open;
23 patients have been enrolled so far.
What other projects
are you excited about and believe will benefit
patients? I think the excitement is
around the addition of these new agents in
treatments for patients with newly diagnosed
disease where combinations might be able to
result in complete remissions, and possibly even
durable complete remissions. In the setting of
relapsed disease, new combinations may allow us
to treat patients with lower doses of each
respective agent to reduce side effects, or use
standard dosing but with improved outcomes as
measured by number and duration of responses.
What are
some of your hobbies and non-research interests?
My hobbies are golf and wine tasting,
only one of which I enjoy doing with my kids. I
also enjoy traveling, which I am able to do a
bit through the myeloma community.
Back to the
top
TAP Advancing Clinical
Trials
The LLS Therapy Acceleration
Program's Academic
Concierge Division
continues to successfully leverage LLS
research investments by helping select
LLS-funded academic investigators move new
therapies toward market approval. On April 22,
2009, LLS will present one of its Academic
Concierge projects, headed by Principal
Investigator Aaron D. Schimmer, F.R.C.P.C.,
M.D., Ph.D., Ontario Cancer Institute (shown
here), at a meeting with Health Canada (the
Canadian equivalent of the U.S. Food and Drug
Administration) and discuss next steps toward
opening a Phase I clinical trial. Barring
any concerns from Health Canada, the program is
on track to open LLS's first AC Division
clinical trial in the fall of 2009.
In
conjunction with the LLS National Board of
Directors meeting held March 13th in Newark,
N.J., the Therapy Acceleration
Program Governance Committee reviewed the
progress of the Cleveland Clinic partnership in
the Clinical
Trials Program Division and approved a
third LLS-supported trial to open at the
Clinical Trial Center for Hematologic
Malignancies. This Phase I/II trial will
combine two approved therapies, Lenalidomide and
Rituximab, for maintenance therapy following
high-dose chemotherapy and autologous stem cell
transplantation in patients with B-cell
non-Hodgkin's lymphoma.
Also exciting is
news that the Cleveland Clinic will utilize
three of its community treatment centers when it
becomes a trial site for LLS's partner, Aegera
Therapeutics, and the ongoing Phase
I/II trial of a new drug (AEG35156)
. The
Cleveland Clinic's main campus and three
regional hospital centers will begin recruiting
patients with relapsed or refractory chronic
lymphocytic leukemia (CLL), small lymphocytic
lymphoma or follicular lymphoma for treatment
with Aegera's AEG35156, that inhibits a molecule
called X-Linked Inhibitor of Apoptosis (XIAP).
This is a significant step toward LLS's goal of
enhancing access to clinical trials by "taking
the trial to the patient."
In order to
leverage its successful clinical trial
partnership with the Cleveland Clinic and to
further address issues that currently limit
clinical trial participation, LLS hosted a 1 1/2
day workshop this past February in San
Francisco. Ron Levy, M.D., professor and chief,
Division of Oncology at Stanford University, led
discussions in which clinical trials experts
reviewed ongoing models for early phase blood
cancer treatment trials, including roles
for-profit companies and government agencies can
play, and considered how LLS can best use its
resources to help increase participation in
practice-changing trials. Workshop discussions
provided many insights that will enable future
partnerships for the LLS Clinical Trials
Program.
Back to the
top
| | |
Cancer Clinical
Trials Bills Introduced in Congress
We all know that clinical trials are
the roadmap to cures for blood cancers. However,
only 3 to 5 percent of adult cancer patients
enroll in a clinical trial. The denial by
insurers of "routine care costs," such as blood
tests, doctor visits and radiological services,
can prevent patients from exploring the option
of participating in these cutting-edge
treatments due to the fear of paying for
procedures out-of-pocket.
Increasing
patient access to cancer clinical trials is a
primary focus of LLS's legislative activities.
This goal was laid out in LLS's latest Strategic
Plan and much of the movement has centered on
state-based advocacy campaigns. To date, 24
states and the District of Columbia have either
passed laws or consensus agreements requiring
private insurers to cover routine care costs for
patients enrolling in a clinical trial. But
these bills only affect cancer patients covered
by state-based healthcare plans, leaving about
50 percent of the American workforce
unaffected.
To address this problem, Sen.
Sherrod Brown (D-OH) introduced the Cancer
Clinical Trials Act (
S
488)
on February 26. The bill would prevent
healthcare plans - both ERISA and
state-regulated - from denying patients enrolled
in clinical trials services that would have been
covered under their plan had they participated
in what is considered standard therapy.
Companion legislation ( HR
716)
has been introduced in the U.S. House of
Representatives by Rep. Steve Israel
(D-NY).
LLS supports any legislative
initiative to increase patient access to
clinical trials. However, the legislation
introduced by Brown and Israel are the most
comprehensive bills addressing the problem, to
date, and would protect all Americans with
health coverage.
ACT NOW! Urge
Congress to Co-Sponsor Access to Cancer Clinical
Trails Legislation TAKE
ACTION
Back to the
top
| | |
| | | |
|
|
 |
|
You are currently receiving
national news from LLS. Your
local chapter may also produce a local
eNewsletter called The Chapter
Report. If you'd like to receive
The Chapter Report please contact your
local chapter to subscribe.
Click here to
find your chapter's contact information.
|
Supported by an
unrestricted educational grant from  |
 |
|
eNEWSLINE is
published by The Leukemia & Lymphoma
Society® Home Office • 1311 Mamaroneck Avenue
• White Plains, NY
10605 914.949.5213 • www.LLS.org
© 2009 The Leukemia
& Lymphoma Society All Rights
Reserved
|
|
 |
| Participating member of An Alliance of
America's Premier Health Charities in the
Combined Federal Campaign, the National
Coalition for Cancer Research and Blood Cancer
Coalition. This publication is designed to
provide information in regard to the subject
matter covered, and is distributed as a public
service by The Leukemia & Lymphoma Society,
with the understanding that LLS is not engaged
in rendering medical or other professional
services.
The Leukemia &
Lymphoma Society® (LLS) is
the world's largest voluntary health agency
dedicated to blood cancer. The LLS mission: Cure
leukemia, lymphoma, Hodgkin's disease and
myeloma, and improve the quality of life of
patients and their families. LLS funds
lifesaving blood cancer research around the
world and provides free information and support
services.
Founded in 1949 and
headquartered in White Plains, NY, LLS has
chapters throughout the United States and
Canada. To learn more, visit www.LLS.org or
contact the Information Resource Center at (800)
955-4572, Monday through Friday, 9 a.m. to 6
p.m. ET. www.lls.org. |
 |
|
Visit our
e-Store
& Special Offers page,
where you can support businesses that support
LLS.
Please remember LLS in your will
or as a beneficiary in your retirement plan. For
information, call (888)
773-9958.
| | | | | |
|
| | | | |